8-K

CRH PUBLIC LTD CO 8-K Report (Dec 21, 2006)

Filed December 21, 2006For Securities:CRH

Summary

This 8-K filing from CRH PUBLIC LTD CO (CRH) announces a significant change in its Directorate. Effective January 1, 2007, the company is co-opting Mr. William P. Egan as a non-Executive Director. Mr. Egan, a US citizen aged 61, brings extensive experience from the venture capital and technology sectors, being a founder and general partner of Alta Communications and its predecessor firm. His background includes backing numerous growth companies and holding leadership positions in the National Venture Capital Association. This appointment is notable for investors as it signals a strengthening of the board with an individual possessing a strong track record in identifying and supporting successful growth companies, particularly within the technology and life sciences industries. Mr. Egan's expertise is expected to be valuable to CRH as it continues its strategic development, potentially bringing new perspectives and connections to the company.

Key Highlights

  • 1CRH plc announced the co-option of Mr. William P. Egan as a non-Executive Director, effective January 1, 2007.
  • 2Mr. Egan is a US citizen, aged 61, and a founder and general partner of Alta Communications, a venture capital firm.
  • 3He has a strong background in venture capital, having founded Burr, Egan, Deleage & Co and backed growth companies in IT, life sciences, and communications.
  • 4Mr. Egan is a Past President and Chairman of the National Venture Capital Association.
  • 5He holds board positions with NASDAQ-quoted Cephalon Inc. and Irish venture capital firm Delta Partners Ltd.
  • 6The appointment is expected to enhance the board's expertise in growth company development and venture capital.
  • 7This filing is incorporated by reference into certain CRH registration statements.

Frequently Asked Questions

William P. Egan is a seasoned venture capitalist, founder of Alta Communications and its predecessor firm. His appointment as a non-Executive Director brings extensive experience in identifying and supporting growth companies, particularly in technology and life sciences, which could be beneficial for CRH's strategic direction.

The co-option of Mr. William P. Egan as a non-Executive Director is effective from January 1, 2007.

Mr. Egan serves on the Boards of Directors for Cephalon Inc. (a NASDAQ-listed biopharmaceutical company) and Delta Partners Ltd. (an Irish venture capital firm), among other private companies.

This is a Form 6-K report filed by a foreign private issuer to report material information that is made public or required to be made public in its home country, or is distributed or made available to its security holders. In this case, it's reporting a directorate change.